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Abstract
Background: Obstructive Sleep Apnoea (OSA) has been recognised as a risk factor for cardiovascular diseases such
as hypertension and cardiovascular events such as acute coronary syndrome (ACS). Since it is also known to reduce
exercise tolerance, it is important to establish the prevalence of OSA in ACS patients, particularly in those who are
commencing cardiac rehabilitation (CR) programs.
Methods: Using PRISMA guidelines a systematic search was conducted in order to identify studies that objectively
measured (using polysomnography or portable monitoring) the prevalence of OSA in ACS patients following
hospital admission. A data extraction table was used to summarise study characteristics and the quality of studies
were independently assessed using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. Meta-analysis of
the selected studies was conducted in order to estimate OSA prevalence as a function of the two main methods of
measurement, the severity of OSA, and timing of the OSA assessment following ACS hospital admission.
Results: Pooled prevalence estimates of OSA using the “gold standard” polysomnography ranged from 22% for
severe OSA to 70% for mild OSA, at any time after hospital admission. Similar prevalence estimates were obtained
using portable monitoring, but interpretation of these results are limited by the significant heterogeneity observed
among these studies.
Conclusions: Prevalence of OSA following ACS is high and likely to be problematic upon patient entry into CR
programs. Routine screening for OSA upon program entry may be necessary to optimise effectiveness of CR for
these patients.
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Background
Obstructive sleep apnoea (OSA) describes a syndrome of
nocturnal respiratory interruptions resulting in sleep
fragmentation, daytime hypersomnolence, and oxy-
haemoglobin desaturation, usually unrecognized by the
patient [1]. The prevalence of OSA in the general popu-
lation varies significantly according to variations in
diagnostic criteria [2], but is estimated to be close to one
in five adults [3]. The risk of OSA rises with increasing
body weight; active smoking; diabetes; and age [4] and is
associated with elevated risk of coronary heart disease
(CHD).
Failure to manage OSA may also be of particular im-
portance in secondary prevention of CHD. There is evi-
dence that cardiac rehabilitation (CR) programs that
include an exercise training component may improve
cardiorespiratory fitness, lifestyle risk factor manage-
ment, psychosocial health and potentially reduce the risk
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of recurrent heart attacks. More specifically, there is
convincing evidence for the existence of a dose-response
gradient between volume of exercise and clinical out-
comes in CR patients [5, 6]. Since it is known to reduce
exercise tolerance [7, 8], and therefore volume of exer-
cise, OSA may function as a potential barrier to effective
CR. Indeed, a number of studies with acute coronary
syndrome (ACS) patients, have demonstrated how con-
tinued sleep problems can adversely affect postoperative
recovery, morbidity, and quality of life [9–11].
In order to investigate the prevalence of OSA it is im-
portant to identify the methods for measuring its preva-
lence in epidemiological studies. The “gold standard”
test for diagnosis of OSA is a conventional, fully super-
vised, level I polysomnography (PSG) sleep study
[12] but since referral for PSG can be difficult, incon-
venient, and expensive [13], unattended portable level II
to level IV devices are often utilised instead. In addition,
the severity of OSA is quantified by the apnoea-
hypopnoea index (AHI), which is the number of breath-
ing cessations (apnoea) and reduced airflow (hypopnoea)
events per hour. An AHI of 5–15 indicates mild disease,
15–30 indicates moderate disease, and > 30 indicates se-
vere disease [14]. Any estimate of prevalence must
clearly indicate which of these objective measures and
which AHI cut-offs are used to define OSA.
In addition to the variation in assessment equipment
and severity, much of the variability in prevalence esti-
mations is due to variations in timing of the assessment
in relation to the ACS event or surgical procedure. In
the short-term, physical and emotional recovery is gen-
erally faster when percutaneous coronary intervention
(PCI) I is performed in comparison to coronary artery
bypass graft surgery(CABGS), but this difference usually
dissipates by 12-months post-procedure [15]. There is
also some evidence that this improvement over time in
physical function and more specifically cardiac function,
such as improved ejection fraction, is associated with
significant reduction of OSA severity over the first 6
months post-procedure [16, 17]. Variations in OSA
prevalence would therefore be expected at these key
times: pre-procedure (before surgery), post-procedure
(in the few days after surgery), recovery (in the immedi-
ate 2–8 weeks after surgery, usually when patients are
expected to commence CR or long-term (more than 2
months after surgery).
Secondary analysis of CR patient data has indicated that
sleep disorders such as OSA have the potential to hamper
rehabilitation efforts by affecting treatment adherence,
self-efficacy and psychological wellbeing [18]. Until re-
cently [19, 20], OSA has rarely been mentioned as a risk
factor to be managed among cardiac patients. The wide-
spread absence of OSA as a target for screening in CR
may be due to the relative paucity of prevalence data in
this population. Currently, recommendations and deci-
sions for OSA screening in cardiac patients is based on es-
timates derived from individual disparate studies.
Determination of robust estimates of OSA prevalence in
ACS patients via the highest level of evidence, a rigorous
systematic review and meta-analysis, would therefore be
an important and novel contribution to the evidence base.
Method
We conducted this meta-analysis in accordance with the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses for Protocols 2015 (PRISMA-P) statement
[21]. The checklist of the PRISMA-P guidelines has been
included in the supplemental material (Additional file 1).
Search strategy
We searched the following electronic bibliographic data-
bases: MEDLINE, Embase, CINAHL, the Cochrane Library,
and Google Scholar. The search strategy included medical
subject heading (MeSH) terms relating to obstructive sleep
apnoea and acute coronary syndrome (see Additional file 2).
Boolean operators, such as “AND” and “OR”, were used to
combine search terms as necessary. The search years cov-
ered the period 1995 to April 2019, and there were no lan-
guage restrictions. This systematic review is registered on
Prospero (http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42017057948).
Inclusion and exclusion criteria
Observational studies which consist of either cross-
sectional, cohort or case-control studies of at least n =
30 ACS patients (unstable angina, ST elevation myocar-
dial infarction, non-ST segment elevation myocardial in-
farction) within 6 months of hospital admission were
included. Since central sleep apnoea is a common occur-
rence in addition to OSA in heart failure patients, stud-
ies that primarily examined heart failure patients were
excluded. Studies that provided a total sample of less
than 30 participants were excluded. Also, excluded from
the analysis were studies that failed to provide sufficient
detail regarding definition of OSA, did not provide AHI
cut-off details or did not provide a prevalence estimate.
Where multiple publications arose from a single study,
the primary research paper with the largest sample size
was chosen for inclusion.
Quality assessment
Four reviewers (MLG, AJ, AB, AD) independently judged
the eligibility of all studies. The risk of bias was systemat-
ically evaluated in each eligible study using the Joanna
Briggs Institute (JBI) Prevalence Critical Appraisal Tool
[22] . This tool is a ten-item questionnaire with four pos-
sible responses: yes, no, unclear or not applicable, that as-
sesses limitations related to study design and study
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population, proportion lost to follow-up, degree of ad-
equate compliance, adjustment for potential confounding
factors, and possible conflicts of interest. All articles were
reviewed by at least two authors (MLG & AJ). Disagree-
ments between reviewers were resolved by consensus.
Meta-analysis
Data synthesis was conducted using meta-analysis of pro-
portions via the metaprop command in Stata SE 14.2 23
and reported in tables and Forest plots. The random-
effects model was chosen apriori, since it takes into ac-
count differences in study population, and study designs
[23] which are assumed to be similar in a fixed methods
model. The heterogeneity between studies was assessed
using I2 statistic with values 0–30%, more than 30 to 60%
and more than 60% corresponding to low, moderate and
high degree of heterogeneity [24]. To explore potential
sources of heterogeneity, sensitivity and subgroup analyses
of the prevalence were carried out. Sensitivity analyses
were conducted to examine the effect of study quality, by
using a method similar to that employed by Patsopoulos
and colleagues [25] which involves comparing the pooled
prevalence before and after elimination of studies with a
rating less than 7/10. Subgroup analysis was conducted
where there were sufficient numbers and were categorised
by primary OSA assessment technique (PSG versus port-
able monitor), time of assessment (in hospital versus at
least 2months post-hospitalisation) and assessment dur-
ing CR program attendance A p value of < 0.05 indicated
significant heterogeneity between studies [26]. Meta-
regression was performed to determine whether possible
covariates such as the timing of assessment, sample size,
mean age, proportion of women, and study quality could
explain the heterogeneity between studies. To assess pub-
lication bias among the studies included in the meta-
analysis, asymmetry of funnel plots was assessed using
Begg’s rank correlation analysis and linear regression ana-
lysis (Egger’s method). Since prevalence of OSA during
CR was of particular interest a subset of studies that in-
cluded prevalence estimates at any time during CR was
identified for further analysis.
Results
Characteristics of the included studies
A total of 552 articles were retrieved by literature search
(Fig. 1) Of these 128 were screened and 75 retained for
Fig. 1 Process of identifying studies for inclusion in the review and meta-analysis
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full-text evaluation. Finally, after a detailed full-text
evaluation using the JBI Prevalence Critical Appraisal
Tool (see additional file 3) a total of 40 articles published
between 1997 and May 2019 were included in the meta-
analysis.
Summary details of the included studies are shown in
Table 1 with further details of studies that provided
prevalence estimates in Additional file 4. Countries from
all regions of the world were represented, with most
studies located in North America, South East Asia and
Europe. The majority of studies were observational pro-
spective cohort or case-control designs. Approximately
two thirds of the selected studies used portable monitor-
ing rather than polysomnography and a number of these
assessed more than one level of OSA severity. Assess-
ment was most commonly conducted within the first
week of hospitalisation and females represented just
one-fifth (20.6%) of all patients.
OSA prevalence estimates
The meta-analysis calculated the pooled prevalence of
OSA mild (AHI > 5), moderate-to-severe (AHI > 15), and
severe (AHI > 30) in ACS patients assessed by either
polysomnography (Fig. 2) or portable home monitoring
(Fig. 3) following surgical intervention. Similar pooled
prevalence estimates for OSA were obtained for both
methods at the moderate (close to half of all patients for
both) and severe cut-off levels (over a fifth of all
patients) (see Table 2). Study heterogeneity was acceptable
for the polysomnography estimates but was moderate to
high for portable monitoring.
Sensitivity analyses
The sensitivity analysis revealed no significant changes
to the prevalence estimates when lower quality studies
were removed (Table 2). Further, a meta-regression indi-
cated that JBI quality of study rating did not significantly
influence prevalence estimates (β = − 0.007 (95% CI −
0.038 to 0.024), p = 0.650). The effect of timing of OSA
assessment was also examined (Table 3). The prevalence
of mild OSA using polysomnography within 2 weeks of
the ACS event, was 5% lower than at greater than 2
weeks of the OSA event. Using portable monitoring, a
significant rise (13%) in mild OSA prevalence was ob-
served over time. In contrast, for the moderate OSA es-
timates, there were decreases in the prevalence estimate
over time, 8% using polysomnography and 1% using
portable monitoring. The severe OSA estimates in-
creased by 2%. A regression analysis on the effect of
timing on the moderate OSA prevalence estimate
using portable monitoring revealed a negative slope
(β = − 0.05) with estimates declining over time but this
was not significant (p = 0.851). Using the data restricted to
moderate OSA, a meta-regression was also performed
using percentage of female participants in each study.
There was a significant negative slope β = − 0.05 (95%
CI − 0.009 to − 0.002), p = 0.002) indicating that pre-
valence estimates decreased as percentage of females
increased (see Fig. 4).
Publication bias
No significant publication bias was detected using
either Begg’s or Egger’s methods for assessing funnel
plot asymmetry (Table 2). method. Further, visual
inspection of the funnel plots indicated that they were
symmetrical.
Probability of OSA upon entry to CR programs
Four studies had assessed the probability of an OSA
diagnosis associated with attendance at CR programs,
but only two had made the assessments upon entry to
CR (Table 4). Estimates of those at risk of OSA upon
CR entry ranged from 53 to 65% of participants. When
portable monitoring was utilised estimates of mild OSA
ranged from 44 to 66%, and moderate to high OSA
ranged from 33 to 75%. The one study that utilised poly-
somnography [27] found that close to three-quarters of
participants had a diagnosis of mild OSA upon entry to
the CR program. In accordance with the overall PSG
and portable monitoring prevalence estimates for all
ACS patients, the study using Holter ECG monitoring
[28] classified 50% of the CR patients as having at least
moderate to severe OSA before entry into CR (see
Table 4).
Table 1 Characteristics of studies included for the prevalence
estimates
Apnoea-hypopnoea index (AHI)
Mild OSA
(AHI ≥5)
Moderate to
severe OSA
(AHI ≥15)
Severe OSA
AHI ≥30)
Assessment method
Polysomnography 7 (44%) 10 (34%) 3 (33%)
Portable monitor 9 (56%) 19 (66%) 6 (67%)
Timing of assessment
(after hospital admission)
Pre-operation 0 (0%) 2 (7%) 0 (0%)
< 1 week 8 (50%) 13 (43%) 6 (67%)
1–3 weeks 4 (25%) 9 (30%) 1 (11%)
> 3 weeks 4 (25%) 6(20%) 2 (22%)
Gender
Female n cases 616 (26.9%) 1567 (18.5%) 287 (21.1%)
OSA Obstructive sleep apnoea, AHI Apnoea/hypoxia index
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Discussion
This meta-analysis confirmed a high prevalence of OSA
in ACS patients that persisted within the first six weeks
following hospital admission. Close to two-thirds of ACS
patients exhibited mild to moderate OSA. What are the
mechanisms that could potentially explain this high
prevalence level in ACS patients? It is though that the
prominent features of OSA, intermittent hypoxia and
sleep fragmentation, could affect a number of patho-
physiological pathways including metabolic dysfunction
[29], sympathetic activation [30], inflammation [31] and
oxidative stress [32]. It is known that even mild levels of
OSA with minimal daytime symptoms are associated
with adverse effects on endothelial function and hyper-
tension [33, 34]. Importantly, higher risk of recurrent
ACS has been found at this mild AHI cut-off level com-
pared to patients with no symptoms of OSA [35].
Alarmingly, close to half of all patients were diagnosed
with moderate to severe OSA, a level that has been inde-
pendently associated with 2.3 times the risk of recurrent
ACS events after adjusting for covariates such as age,
sex, BMI, smoking and diabetes [36].
A second major finding from this study concerns the
method of diagnosis of OSA. Remarkably similar esti-
mates of prevalence were obtained using level I “gold
standard” polysomnography and levels II to IV portable
Fig. 2 Forest plot of OSA prevalence in studies using polysomnography by OSA severity sub-groups (Mild AHI =5–14; Moderate AHI = 15–29;
Severe AHI > 30) post-surgical intervention. ES = effect size; OSA = obstructive sleep apnoea; AHI = apnoea/hypoxia index. See Additional File 4
for references
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monitoring, particularly at the moderate and severe AHI
levels. A recent review of OSA assessment in CVD pa-
tients reported considerable intra-individual night-to-
night variability in AHI assessed by polysomnography,
with variability particularly higher in patients with mild
OSA [37]. These findings would imply that longer pe-
riods of assessment, certainly greater than just one night,
are warranted in order to gain a more accurate diagnosis
of OSA or days of burden with OSA. Given the high
congruence in prevalence estimates obtained in this
study, the night to night variability of AHI, and the con-
siderable expense associated with polysomnography over
a number of nights, it may therefore be of more practical
benefit to utilise those portable monitoring devices
which have been found to have good predictive validity
[38] in long term OSA assessment of ACS patients.
Given the high OSA prevalence estimates obtained in
this study it is important to consider the potential impli-
cations for screening of this condition upon entry to CR
programs. A recent systematic review of exercise-based
Fig. 3 Forest plot of OSA prevalence in studies using portable monitoring by OSA severity sub-groups (Mild AHI =5–14; Moderate AHI = 15–29;
Severe AHI > 30) post-surgical intervention. ES = effect size; OSA = obstructive sleep apnoea; AHI = apnoea/hypoxia index. See Additional File 4
for references
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CR programs reported a null effect of such programs on
mortality outcomes [39]. In response to this review it
has been pointed out that exercise dose and adherence
to exercise may have varied significantly across individ-
ual trials, a factor that could explain the heterogeneity in
exercise capacity observed across trials and partially
explain the overall null finding [40]. The high prevalence
of OSA observed in patients attending CR, as noted in
this study (Table 4), would contribute to this heterogen-
eity of exercise adherence and exercise capacity [7, 8]
and undermine the effectiveness of exercise-based CR
programs. In addition, recent meta-analyses have indi-
cated significant reductions in cardiovascular morbidity
[41] and mortality [42] following continuous positive
airway pressure (CPAP) treatment where adequate
adherence was observed. Given the increased risk for
recurrent ACS and the potentially reduced effectiveness
of exercise-based CR treatment it would make sense to
screen for this condition upon entry to out-patient
cardiac rehabilitation programs [19].
There are several potential limitations of this review
that should be addressed. First, the vast majority of stud-
ies selected in this review included studies based in hos-
pital coronary care units. It was not possible to perform
a sub-group analysis on patients attending CR which is
typically 4–8 weeks after hospital discharge. In keeping
with previous findings [16, 17], our meta-regression
findings indicated that OSA prevalence estimates tend to
decline slightly in the weeks following hospital admis-
sion, however this is not a significant decrease.
Individual studies that utilised objective measurement
[27, 43, 44] and questionnaires [45–47] support the con-
clusion that OSA prevalence is high upon entry to CR
programs. Second, our meta-regression confirmed that
any estimate of OSA prevalence is influenced by gender
mix, with lower prevalence rates obtained when greater
percentages of females are included in the study. The
majority of studies selected in this review include pre-
dominantly male patients and there were not enough
studies to conduct a meta-analysis where equal gender
balance was reported. It is known that women are less
likely to be referred for revascularization for ACS than
men [48], so it is likely that this issue will persist in fu-
ture studies. Third, due to lack of specific reporting of
OSA by diagnostic category in the majority of studies,
we were not able to perform sub-group analysis compar-
ing levels of severity of ACS severity. Limited evidence
does suggest that severity of OSA may be marginally
higher in CABGS patients than PCI patients [49, 50],
however this is confounded by insufficient testing in
patients who perceive themselves to be asymptomatic
and do not participate in studies [49].
Finally, it is important to acknowledge the consider-
able heterogeneity across the studies included, particu-
larly among studies that utilised portable monitoring.
Efforts to account for this heterogeneity including sub-
group analysis could not effectively reduce heterogeneity
statistics obtained. Given the large variety of type II
through to type IV portable devices utilised with varied
number of channels recorded [51], varying predictive
Table 2 Prevalence estimates as a function of OSA severity and method of assessment
No.
studies
Random pooled
prevalence (95% CI)
Significance tests
of prevalence = 0
Heterogeneity
Statistic (Q)
I^2a Sensitivity
prevalenceb
Rank correlation
test (Begg)
Reg test for funnel
plot asymmetry (Egger)
Mild OSA
AHI ≥ 5
PSG 7 0.66 (0.57–0.74) z = 14.91, p <
0.001
51.24, p <
0.001
88.29% 0.66 (0.57–
0.74)
0.23, p = 0.517 −1.5, p = 0.125
Portable
monitor
9 0.63 (0.57–0.69) z = 19.13, p <
0.001
46.18, p <
0.001
82.68% 0.63 (0.57–
0.68)
−0.16, p = 0.612 −0.6, p = 0.566
Moderate OSA
AHI ≥ 15
PSG 10 0.47 (0.44–0.50) z = 29.78, p <
0.001
8.16, p =
0.520
0.01% 0.47 (0.43–
0.50)
0.16, p = 0.601 0.6, p = 0.529
Portable
monitor
19 0.50(0.45–0.55) z = 19.27, p <
0.001
81.13, p <
0.001
94.59% 0.49 (0.44–
0.55)
0.02, p = 0.965 0.1, p = 0.925
Severe OSA
AHI ≥ 30
PSG 3 0.22 (0.17–0.27) z = 8.74, p <
0.001
2.49, p =
0.287
22.70% 0.22 (0.17–
0.27)
0.98, p = 0.333 1.5, p = 0.141
Portable
monitor
6 0.21 (0.14–0.28) z = 5.82, p <
0.001
34.77, p <
0.001
85.62% 0.21 (0.13–
0.28)
0.14, p = 0.103 1.98. p = 0.080
a I^2: the variation in ES attributable to heterogeneity; PSG Polysomnography, OSA Obstructive sleep apnoea, AHI Apnoea/hypoxia index
b Sensitivity analysis: removal of 8 studies with quality rating below 7/10
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Table 3 Effect of time of assessment after surgical procedure on prevalence estimate
Time after procedure No. studies Random pooled prevalence (95% CI) Significance tests of prevalence = 0 Heterogeneity
statistic
df P I^2*
Mild OSA AHI ≥ 5
PSG
Within 2 weeks 2 0.67 (0.61–0.72) z = 24.01, p = 0.00 – – – –
> 2 weeks 4 0.72 (0.67–0.76) z = 28.72, p = 0.00 4.22 3 0.24 28.94%
Test for heterogeneity between timing sub-groups 1.51, df = 1, p = 0.22
Portable
Within 2 weeks 6 0.59 (0.53–0.65) z = 19.80, p = 0.00 16.24 5 0.01 69.22%
> 2 weeks 3 0.72 (0.55–0.89) z = 8.43, p = 0.00 – – – –
Test for heterogeneity between timing sub-groups 2.01, df = 1, p = 0.16
Moderate OSA AHI ≥ 15
PSG
Within 2 weeks 4 0.51 (0.45–0.57) z = 16.75, p = 0.00 4.37 3 0.22 31.28%
> 2 weeks 6 0.43 (0.39–0.48) z = 19.98, p = 0.00 4.40 6 0.49 0.01%
Portable
Within 2 weeks 16 0.50 (0.44–0.56) z = 16.84, p = 0.00 36.77 15 0.00 95.26%
> 2 weeks 3 0.49 (0.43–0.54) z = 18.73, p = 0.00 – – – –
Test for heterogeneity between timing sub-groups 0.20, df = 1, p = 0.65
Severe OSA AHI ≥ 30
PSG & Portable combined
Within 2 weeks 8 0.22 (0.15–0.29) z = 6.47, p = 0.00 39.26 7 0.00 84.72%
> 2 weeks 2 0.24 (0.18–0.30) z = 7.41, p = 0.00 – – – –
Test for heterogeneity between timing sub-groups 0.16, df = 1, p = 0.69
a I^2: the variation in ES attributable to heterogeneity; PSG Polysomnography, OSA Obstructive sleep apnoea, AHI Apnoea/hypoxia index
Fig. 4 Meta-regression of percentage female included in each study and effect on moderate OSA (AHI 15–29) prevalence estimate. OSA =
obstructive sleep apnoea; AHI = apnoea/hypoxia index
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validity [38], used by different health professionals and
the variety of conditions in which they were utilised (e.g.
at home, in hospital, expert assisted or not) it may not
be possible to effectively control for this study hetero-
geneity. It is important to note that acceptable hetero-
geneity was observed for polysomnography where
similar prevalence estimates were obtained. Finally, the
traumatisation of hospitalisation and surgical interven-
tion is often associated with sleep disturbances which
can include OSA and insomnia.
Conclusions
OSA was found to be highly prevalent in ACS patients
immediately following surgical intervention and remains
high in the period where entry to CR programs is typ-
ical. Given the evidence that OSA has a deleterious im-
pact upon exercise capacity and adherence and adversely
affect CR efforts,, but can be effectively treated, it may
be advisable to screen for this condition upon CR
program entry.
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